Long QT syndrome (LQTS) is a genetic disease characterized by a prolonged QT interval in an electrocardiogram (ECG), leading to higher risk of sudden cardiac death. Among the 12 identified genes causal to heritable LQTS, ∼90% of affected individuals harbor mutations in either KCNQ1 or human ether-a-go-go related genes (hERG), which encode two repolarizing potassium currents known as I Ks and I Kr . The ability to quantitatively assess contributions of different current components is therefore important for investigating disease phenotypes and testing effectiveness of pharmacological modulation. Here we report a quantitative analysis by simulating cardiac action potentials of cultured human cardiomyocytes to match the experimental waveforms of both healthy control and LQT syndrome type 1 (LQT1) action potentials. The quantitative evaluation suggests that elevation of I Kr by reducing voltage sensitivity of inactivation, not via slowing of deactivation, could more effectively restore normal QT duration if I Ks is reduced. Using a unique specific chemical activator for I Kr that has a primary effect of causing a right shift of V 1/2 for inactivation, we then examined the duration changes of autonomous action potentials from differentiated human cardiomyocytes. Indeed, this activator causes dose-dependent shortening of the action potential durations and is able to normalize action potentials of cells of patients with LQT1. In contrast, an I Kr chemical activator of primary effects in slowing channel deactivation was not effective in modulating action potential durations. Our studies provide both the theoretical basis and experimental support for compensatory normalization of action potential duration by a pharmacological agent. stem cells | drugs
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stem cells | drugs T he biophysical characteristics of an action potential (AP) are controlled by contributions of different ionic currents. In the human cardiac system, synchronized firing and conduction of APs of electrically coupled cardiomyocytes give rise to rhythmic contraction, which is commonly monitored by the surface electrocardiogram (ECG). Rapidly activating K + current (I Kr ) and slow delayed rectifier K + current (I Ks ) are major components of AP repolarization and hence have roles in determining AP duration (APD) (1, 2) . Reducing their contributions pharmacologically or genetically is reflected in a lengthening of the Q-T interval between the QRS complex and the T wave in the ECG. Long QT syndrome (LQTS) caused by prolongation of APD has a prevalence of 1 in 5,000 among the general population. As a predisposed condition, patients with LQT have a high incidence of sudden cardiac death. Among 12 different genes causal to LQTS, remarkably, 90% of patients harbor mutations in KCNQ1 or KCNH2 [human Ether-a-go-go-Related Gene (hERG)] genes, causing a reduction in either I Ks or I Kr currents. Therefore, understanding the contributions of repolarizing ionic currents and potential compensatory effects between them is of considerable interest.
Reduction of the I Ks current due to mutations in KCNQ1 has been reported in 40-55% of patients with LQT and represents the most frequent cause of congenital LQTS (3). In both rabbit and guinea pig, the I Ks component is present in adult cardiomyocytes. Indeed, reduction of KCNQ1 expression resulted in prolongation of the QT interval (4). However, several important features of human cardiac function including diversity of genetic mutations of I Kr or I Ks and drug-induced LQT phenotype cannot readily be reproduced or modeled in animal systems (5) . R-L3 is an active compound that was reported to potentiate I Ks in guinea pig and had similar effects on KCNQ1. However, it was not effective on the oligomeric KCNQ1/KCNE1 channel, the molecular determinant for I Ks (6) . Phenylboronic acid (PBA) activates KCNQ1/ KCNE1 complexes at millimolar effective concentrations (7) .
Using induced pluripotent stem cells (iPSCs) derived from members of a family affected by LQT syndrome type 1 (LQT1) and harboring an R190Q heterozygous missense mutation in KCNQ1, we generated and investigated functional cardiomyocytes. The patient-derived cells recapitulated the electrophysiological features of the disorder with noticeably prolonged APs (8) . By recording autonomous beating cardiomyocyte clusters displaying ventricular features, we investigated the feasibility of quantitatively analyzing both control and LQT1 action potentials. On the basis of this model system, we then tested whether the specific perturbation of hERG channel gating would effectively rescue the LQT1 disease phenotype.
Results
Quantitative Analyses of Compensatory Effects Between I Ks and I Kr . A detailed characterization of different ionic components in differentiated human cardiomyocytes from pluripotent stem cells has not been reported. We compared the expression of genes generating the cardiac I Kr (HERG1a and HERG1b) and I Ks (KCNQ1) currents in cardiac myocytes obtained from control and LQT1 iPSC lines, as well as in adult and fetal human heart. Quantitative real-time PCR (qRT-PCR) analyses revealed that HERG transcript levels were similar between control and LQT1 cardiomyocytes (Fig. 1A) , which is consistent with the earlier data of similar I Kr current densities in control and LQT1 cells (8) . Therefore, the subsequent analyses use the same I Kr value for both the healthy control and LQT1 in modeling. To assess the contributions of different current components in a typical ventricular-like AP, we recorded spontaneous electrical activity of human cardiomyocytes derived from iPSCs. We then used the model first developed by ten Tusscher, which describes a variety of electrophysiological behaviors of adult human ventricular cardiomyocytes (9) . One unique feature in differentiated cardiomyocytes is the autonomous contraction absent in acutely isolated human cardiomyocytes, consistent with the notion that differentiated myocytes in culture are not mature (10) . Some components in the ten Tusscher model were modified to match the recorded spontaneous APs. Inclusion of a late sodium current component (I NaL ) and a funny current component (I f ) afforded a better cross-examination between model-based simulation and the recorded action potential (SI Experimental Procedures). With the modifications outlined in Table S1 , the simulated AP traces agree well with those of the representative APs recorded in control cell clusters (Fig. 1B) . The key parameters include APD 90 = 388.4 ms and action potential amplitude (APA) = 82.5 mV for simulated traces and APD 90 = 377.3 ± 14.0 ms and APA = 79.6 ± 1.6 mV for recorded traces (Table 1) . To model LQT1 APs, we reduced I Ks by 30% of control, the level of I Ks measured in LQT1 iPSC-derived myocytes with the R190Q-KCNQ1 mutation (11) . This procedure resulted in a simulated action potential of APD 90 = 523.6 ms and APA = 84.9 mV that matches well with the recorded trace of LQT1 cells with APD 90 = 530.6 ± 18.8 ms and APA = 82.8 ± 2.2 mV (Fig. 1) . The agreement between experimental data and simulated data supports the applicability of the modified model for quantitative analyses.
Therefore, we examined the robustness of the modified model by testing how reduction of I NaL or increase in I Kr would affect action potential in control or LQT1 cardiomyocytes. In adult human cardiomyocytes I NaL is ∼0.055 nS/pF (11) . Fig. 2A shows that when I NaL is enhanced approximately sixfold (0.33 nS/pF) as seen in F1473C mutation in the SCN5A gene that leads to LQT3 (12), the control displays clear prolongation of APD. Specific sodium channel block therefore reduces this component and brings the duration back to 400 ms, similar to control values ( Fig.  2A) . However, in the LQT1 model, where I Ks is reduced to 30%, the reduction of the normal I NaL level was less effective on APD (Fig. 2B ), consistent with an earlier report (13) . Similarly, the I NaL reduction had no significant effect on APD of the control either. This model-based prediction is in agreement with that of the experimental data, where specific sodium channel blockers are more effective to correct the defects in patients with LQT3 (14) . In addition to I NaL , I Kr is another component critical for determining APD. Therefore, we examined whether an increase in repolarizing I Kr could normalize the prolonged APD in LQT1 cardiomyocytes. The hERG potassium channel is the primary molecular determinant responsible for the I Kr . A biophysical property of hERG absent in KCNQ1 is the rapid inactivation during depolarization. Thus, changing in channel inactivation by shifting its voltage sensitivity (V 1/2 ) to a more positive value would slow the inactivation and increase channel availability during the repolarizing phase of the AP. To examine this, we progressively shifted the V 1/2 from −87 mV to −70 mV, −40 mV, and −10 mV. The model predicts progressive shortening of APD in control cells (Fig. 2C) . Importantly, in LQT1 cells the rightward shift of inactivation V 1/2 could also progressively shorten the APD into the normal range (Fig. 2D) . Another way to increase I Kr density during the AP is to slow down the deactivation rate of hERG current. Thus, we simulated the effect of decreasing I Kr decay rate on APD by increasing the time constant of the activation (deactivation) gate, τx r1 . This change is not sufficient to shorten prolonged APDs in LQT1 cardiomyocytes. Instead, the model predicts a flattering of phase 4 diastolic depolarization and a reduction of firing frequency (Fig. 2E ). This prediction is consistent with an earlier study demonstrating that I Kr decay rate is one of the key determinants of the speed of pace-making depolarization (15) . The simulation, despite the fact that some values used were based on empirical estimation or Key parameters are summarized of a simulated or recorded action potential from a healthy control and a patient with LQT1. For the simulation study, the values were obtained in the steady state. For the experimental study, the values were based on the real recording from small beating clusters of myocytes.
on earlier reports, is consistent with the experimental evidence that a sodium channel blocker is more effective in patients with LQT3, indicative of gene-specific rescue. In contrast, it argues an increase of I Kr would be able to correct the APD in LQT1 cardiomyocytes. Importantly, the model specifies that a rightward shift of I Kr inactivation V 1/2 and not a slower deactivation rate is effective in restoring the prolonged APD in LQT1 patients to a normal range.
Identification of a Specific Gating Modulator. Using automated electrophysiology, we have conducted a large compound library screen to identify and characterize small molecule modulators for hERG potassium channels (16) . Although a vast majority of modulators were inhibitors, a small number of activators have been identified in the primary screen. On the basis of the model, we examined and selected hits that have biophysical characteristics consistent with affecting voltage sensitivity of inactivation. One scaffold with unique core structure was confirmed with a resynthesized compound. We then purchased or synthesized various derivatives to examine both potency and efficacy, using automated electrophysiology. ML-T531 (or CFK332-B) is one potent activator with highest efficacy (EC 50 = 3.13 ± 0.47 μM (Table 2) and was selected for further investigation.
To experimentally characterize the specificity of ML-T531 on I Kr and I Ks , we performed manual voltage clamp recording of hERG currents, using a standard protocol with a Chinese hamster ovary (CHO) cell line stably expressing hERG channels. For comparison, recordings were made from a CHO cell line coexpressing cDNAs of KCNQ1 and KCNE1, the molecular determinants for I Ks (17, 18) . Fig. 3A shows that in the absence of compound, hERG currents display a current-voltage relationship in agreement with the literature. In the presence of ML-T531, a dramatic increase in steady-state current was observed. In contrast, under the same conditions, KCNQ1/E1 coexpression exhibited no potentiation, but a slight current reduction was observed (Fig. S1 ). In addition, ML-T531 has no noticeable effects on other cardiac channels including Cav1.2, Kir2.1, Nav1.5, and Kv4.3. These channels are the molecular determinants for I Ca , I K1 , I Na , and I to (Fig. S2) .
To further characterize ML-T531 effects on hERG channels, steady-state current density was plotted against voltages from −80 mV to +40 mV (Fig. 3B) . The enhancement of current was much more pronounced at positive compared with negative voltages. To examine whether ML-T531 affects the conductance-voltage (G-V) relationship, the relative conductance at −50 mV was plotted against step voltages (Fig. 3C) . ML-T531 at 10 μM caused no detectable change in the activation V 1/2 . Further characterization of ML-T531 effects on inactivation and deactivation was performed by measuring the time constants in the presence or absence of 10 μM ML-T531. Fig. 3D shows that ML-T531 slowed down the deactivation rate at all voltages tested, indicating its capability to increase occupancy of the channel open states (Fig. S3) . Furthermore, it caused a rightward shift of inactivation V 1/2 by 28 ± 1.0 mV (n = 8) (Fig. 3E and Fig. S4 ). On the basis of the results obtained from heterologously expressed channels, we simulated the effects in LQT1 cells (Table 1) .
Action Potential of iPSC-Derived Control and LQT1 Cardiomyocytes.
To examine the effects of ML-T531 on native currents, we performed single-cell voltage clamp experiments measuring native I Kr and I Ks currents from healthy human iPSC-derived cardiomyocytes. Using a published protocol for human iPSC-derived cardiomyocytes (19) , the combined potassium currents mainly contributed by I Ks and I Kr were isolated (SI Experimental Procedures and Fig. 4 ). In the presence of 10 μM ML-T531, the current density consistently increased at all voltages tested for both steady-state and tail currents (Fig. 4 A and B) . Moreover, under these conditions ML-T531 enhanced voltage-dependent potassium current amplitudes in the presence of an I ks -specific inhibitor chromanol 293B. The activation kinetics and rectification properties of the enhanced current are consistent with those of I Kr (Fig. S5) . These results combined with specificity tests (Fig.  S2 ) argue for I Kr augmentation being the primary effect of ML-T531 in native human cardiomyocytes. To examine whether the LQT1 phenotype could be rescued by the compensatory effect of increasing I Kr , we recorded the spontaneous action potentials of human cardiomyocytes derived from both control and LQT1 iPSCs (8) . The experiments were carried out using spontaneously beating cardiomyocytes with ventricular-like action potentials. These cells have APA greater than 70 mV, maximum diastolic potential (MDP) more negative than −50 mV, and APD 90 / APD 50 smaller than 1.25. Consistent with earlier reports (8), The holding potential was −60 mV. Steady-state currents were examined from −10 mV to +50 mV in 20-mV increments, whereas tail currents were elicited at −30 mV. Except for I Kr and I Ks , other major ionic components including I Na , I K1 , I to , and I CaL were pharmacologically suppressed under the recording conditions (Experimental Procedures). (B) Summary of the compound effects on steady-state current (Upper) and tail current (Lower) at the indicated voltages (n = 11). (*P < 0.05; **P < 0.001).
Fig
. 5B shows that LQT1 patient-derived cardiomyocytes displayed significantly longer APD values (APD 90 = 530.6 ± 18.8 ms, n = 26) compared with those derived from the healthy control individual (APD 90 = 377.3 ± 14.0 ms, n = 14). Next, we investigated the effect of 10 μM ML-T531 on spontaneous APs of LQT1 cardiomyocytes. ML-T531 significantly shortened the APD of the diseased cardiomyocytes and normalized the APD values comparable to those recorded from the healthy control ( Fig. 5 A and C and Table 1 ). In addition, ML-T531 caused a hyperpolarizing shift in the MDP values ( Fig. 5C and Table 1 ). The above two major effects are consistent with our modeling results for a compound that causes a rightward shift in inactivation V 1/2 and thereby enhances potassium currents during repolarization. Indeed, when the compound effects on recombinant hERG were incorporated into the model, the predicted AP parameters during compound treatment correlated well with those obtained experimentally (Table 1) . Furthermore, ML-T531 shortened the APD 90 of LQT1 cardiomyocytes in a dose-dependent manner (Fig. 5D) . When fitted by the Hill equation, the dose-response curve gives rise to an EC 50 value of 5.71 ± 1.42 μM (Fig. 5E) , which is comparable to the EC 50 (3.13 ± 0.47 μM) obtained in a CHO recombinant system. The similarity of EC 50 values measured in LQT1 human cardiomyocytes to that in hERG-CHO cells supports that I Kr or hERG is the major target of this compound in native cells. Taken together, our results demonstrate the possibility of normalizing the LQT1-related disease phenotype by targeting the voltage dependence (V 1/2 ) of inactivation of hERG channels.
Discussion
The modified ionic components in the current model relative to the ten Tusscher model are consistent with the notion that in vitro differentiated cardiomyocytes display electrophysiological characteristics that are closer to the fetal counterparts (10) . These characteristics include a lower I K1 component, reduced value of dV/dt during the initial stage of action potential, and more depolarized MDPs. The revised model enables several valuable predictions testable by experiments using human cells. Almost all model parameters were based on published work with a few modifications (9) . The conductance of the I K1 value was reduced to 3% of the normal value. This change is supported by the autonomous beating commonly seen in these cells and agrees with results of RT-PCR studies that suggest a noticeable reduction of normal levels of I K1 (20) . The I CaL component was doubled in the simulations to account for the consistently longer APDs recorded from control cells compared with the original model. The revised values, even though some have qualitative support, were assigned artificially to achieve closer correlation between modeled and recorded action potential traces, either in the presence or in the absence of the compound treatments (Table S1 ). Future directions may include quantification of individual current components so that a more refined model may be established. Because the initial variables for this quantitative analysis were directly adapted from the original ten Tusscher model, clearly our simulated action potentials tend to gradually reach a steady state and gain some immature phenotypes, such as a depolarized MDP and a slower dV/dt max ( Fig. S6 A-F) . Under steady state, while we note that LQT3 phenotype become less severe, which is likely due to reduced I NaL availability under relatively deporlarized MDP, the conclusion remains essentially true; i.e., modulation of voltage dependence of inactivation is more effective than slowing of deactivation (Fig. S6G) . To examine whether the general conclusion could be applicable to adult cardiomyocytes, we also tested the idea using original ten Tusscher values and obtained similar conclusion (Fig. S6H) . Cardiomyocytes have several potassium channels. These channels, although permeable to potassium, typically display distinct gating properties. Therefore, it is possible that compensatory rescue as described in this study requires specific gating modulation achievable by modifying specific biophysical properties of the targeted channel. Indeed, it was noted that 10 μM ML-T531 decreased AP firing frequency (Fig. 5A) , which is consistent with our modeling results, because ML-T531 slows down the I Kr deactivation (Fig. 3D) . To examine this hypothesis more closely, we tested ginsenoside (Rg3), which potentiates hERG current by predominantly slowing the deactivation kinetics ( Fig. S7 A and B) (21) . Indeed, we found that when this compound is applied to the beating cardiomyocytes, the AP firing frequency was greatly reduced (Fig. S7 D and G) . However, there was minimal change in shape or duration of action potentials (Fig. S7 C and F) . This result provides the direct support for use of a specific mechanism of gating modulation to achieve compensatory rescue.
The two potassium currents, I Kr and I Ks , play a critical role in repolarizing the membrane to terminate an AP. Reports suggest a possible interaction between a mutant KCNQ1 channel and hERG, resulting in change of hERG trafficking to the membrane (22) . However, in our LQT1 iPSC-derived cardiomyocyte model, expression levels of genes coding for I Kr were similar to those of control cells (Fig. 1A) as well as I Kr current density, as previously reported (11) . Reduction of I Ks current has been modeled both pharmacologically using a KCNQ1 inhibitor (23) and genetically with transgenic rabbits overexpressing loss-of-function pore mutants of KCNQ1 (4). Using these animal or pharmacological models, the attempts to rescue prolongation of APDs have been carried out using either an I Kr activator (24) or an opener of ATP-sensitive potassium channels (25) . Pharmacological interventions aiming at influencing the APD have been in use for many years, such as class III antiarrhythmics for APD prolongation. The notion of compensatory rescue of prolonged APDs has been previously tested by enhancing K ATP current (26) . Unlike the prolongation of the APD, the pharmacological shortening of a pathologically prolonged APD has been investigated only in very few studies using patient samples that are not readily available (27) . Our results using patient iPSC-derived myocytes with disease phenotypes provide an important proof of principle of a therapeutic intervention to shorten APD.
The hERG activator ML-T531 has a distinct chemical structure compared with the previously described compounds that potentiate hERG currents (28) (29) (30) (31) (32) (33) . The reported activators may be classified according to the modes of action, including slowing of deactivation and modulation of voltage dependence of inactivation. Not all of them have effects on APD in tested animal models. ML-T531 has a pronounced effect on voltage sensitivity of hERG inactivation similar to that reported for ICA-105574. Interestingly, an earlier study has shown that ICA-105574 was capable of shortening APD in isolated cardiomyocytes from guinea pig (28) . In contrast, RPR260243, which primarily acts in slowing hERG deactivation, has pronounced effects on T-wave amplitude in guinea pig hearts but almost no effects on QT duration even at 30 μM, the highest concentration tested (30) . These experiments are in agreement with our results that reduction of voltage dependence for inactivation is more effective in modulating APD.
Whereas I Kr may involve more than the hERG channel, it is thought that the hERG subunits are the primary determinants for the pharmacology of I Kr (34) . We noted that ML-T531 has nearly identical potency (EC 50 ) measured by shortening of action potential in cardiomyocytes and by steady current increase in heterologously expressed hERG channels. This correlation argues for the compound specificity on the native hERG channel in human cardiac cells. Our experiments demonstrate an application of human iPSC technologies by testing compound effects on correcting an abnormal functional phenotype due to an inherited cardiac disorder. Future optimization via structure-activity studies may afford improved potency and specificity, thereby increasing its utility.
Experimental Procedures
The general method of modeling is similar to that used in the ten Tusscher model (9) and SI Experimental Procedures (35) . Human iPS cell lines from the patient with long QT1 syndrome and the healthy control (8) were maintained in feederfree mTeSR1 medium. For whole-cell patch-clamp recordings, beating clusters 2-3 mo old were microdissected and disaggregated as previously reported. Traditional whole-cell voltage-clamp recording was performed at room temperature. Additional details are described in SI Experimental Procedures.
